Only four patients over 60 years (60, 62, 65, and 71 y) were vaccinated against LBH589 yellow fever, and only one who was in good physiological condition and traveled to Benin for 2 weeks received a primary vaccination. In this case the benefit of vaccination was assessed to be superior to risk. All 413 travelers needing vaccination and presenting no contra-indication
were vaccinated (100%, 95% CI: 99–100%). Although South Africa and the Comoros Islands are not endemic for yellow fever and vaccination is not recommended, three patients, however, received yellow fever vaccination without indication as they were traveling to these two countries.9 All the travel destinations were considered as at risk for hepatitis A. As many as 276 patients were considered immune to hepatitis A. Among the non-immune patients (n = 454), 442 patients were vaccinated (97.4%, 95% CI: 95.4–98.5%) against hepatitis A. Five patients refused vaccination (1.1%) check details and vaccination was not proposed to seven patients (1.5%). To improve the services for travelers at our travel medicine and vaccine center, we wanted to increase our knowledge about the adequacy of the advice given to travelers
to national guidelines. We selected three fields of interest: malaria prevention, yellow fever, and hepatitis A vaccinations, which are key to safe travels in the tropics, and performed a 3-month prospective study before summer holidays. These three fields of interest are relevant since 83% of our travelers visited malaria-endemic areas, 74% visited yellow fever-endemic areas, and all of them were exposed to the risk of hepatitis A. Previous studies
have also shown that 35 to 49% of travelers to Africa carried either no or inappropriate prophylaxis.10,11 Overall our results look quite satisfactory since adequacy to national guidelines was above 95% for all three diseases. These results were obtained in the setting of a study of 730 travelers, assessing real prescriptions from physicians. These results compare favorably to results obtained in previous studies assessing the quality of travel medicine, most of which used questionnaires.12–18 Interestingly, doxycycline was the most frequent chemoprophylaxis prescribed for malaria in this study (48% of all prescriptions). This drug is the cheapest anti-malaria prophylaxis Dolichyl-phosphate-mannose-protein mannosyltransferase in France, and is as effective as the other drugs.19–21 It is also well tolerated, with a better tolerability profile than mefloquine.22–24 The limitation for its use is the need to continue treatment for 4 weeks after leaving the malaria-endemic area, with a risk for suboptimal adherence23–24 and travelers who want to sunbathe, because of the risk of phototoxicity. During the 3-month period of the study, 413 travelers received yellow fever vaccination. This represents a large number of vaccinations as compared to travel centers in most parts of Europe.25 There are a number of potential explanations for these good results.